Peroxidase Induced Metabolism and Lipid Peroxide Scavenging by Antitumor Agents

  • Pawel Kolodziejczyk
  • J. William Lown
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 264)


Oxygen is often viewed as being synonymous with life. It is necessary for the living processes of mammals including humans. The arrest of breathing, apart from termination of other functions, is an evident sign of mammalian death. However, soon after death, the body begins to re-utilize oxygen and in a short period it consumes oxygen at much higher rate than in normal life processes. But this process no longer represents controlled biological oxidation. Rather it is uncontrolled autooxidation, peroxidation or free radical oxidation of polyunsaturated lipids. In recent years, interest has grown in the possible links between drug metabolic reactions and certain aspects of lipid biochemistry. Attention has been focused particularly on oxidative processes, namely those of lipid peroxidation and co-oxidation. Lipid peroxidation is now recognized as an important mediator of toxicity.1 Reactive oxygen species (Superoxide anion radical, hydroxyl radical, singlet oxygen and hydrogen peroxide) are produced during enzymatic oxidation of xenobiotics by cytochrome P-450 and other oxidoreductase systems.2


Arachidonic Acid Anticancer Agent Lipid Hydroperoxide Redox Cycling Pyridine Nucleotide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J. S. Bus and J. E. Gibson, Lipid peroxidation and its role in toxicology, Rev. Biochem. Toxicol. 1:125 (1979).Google Scholar
  2. 2.
    H. Kappus, Overview of enzyme systems involved in bioreduction of drugs and in redox cycling, Biochem. Pharmac. 35:1 (1986).CrossRefGoogle Scholar
  3. 3.
    R. W. Estabrook, N. Chacos, C. Martin-Wixtrom, and J. Capdevila, Cytochrome P-450: A versatile vehicle of variable veracity, in Oxygenases and Oxygen Metabolism, M. Nozaki, S. Yamamoto, Y. Ishimura, M. J. Coon, L. Emster, R. W. Estabrook (eds.), Academic Press, New York (1982).Google Scholar
  4. 4.
    T. L. Dormandy, Free-radical oxidation and antioxidants, Lancet 647 (1978).Google Scholar
  5. 5.
    L. Masotti, E. Casali and T. Galeotti, Lipid peroxidation in tumor cells,Free Radical Biol. Med. 4:377 (1988).CrossRefGoogle Scholar
  6. 6.
    P. A. Cerutti, Prooxidant states and tumor promotion, Science 227:375 (1985).PubMedCrossRefGoogle Scholar
  7. 7.
    P. A. Cerutti, Repairable damage in DNA, in DNA Repair Mechanisms,P. Phanawalt, E. Friedberg, C. Fox (eds.), Academic Press, New York (1978).Google Scholar
  8. 8.
    K. Brown and I. Fridovich, Superoxide radical and Superoxide dismutase: Threat and defense, Acta Physiol. Scand. Suppl. 492:9 (1980).Google Scholar
  9. 9.
    I. Emerit, M. Keck, A. Levy, J. Feingold and A. M. Michelson, Activated oxygen species at the origin of chromosome breakage and sister-chromatid exchanges, Mutat. Res. 103:165 (1982).PubMedCrossRefGoogle Scholar
  10. 10.
    I. Emerit, A. Levy and P. A. Cerutti, Suppression of tumor promoter phorbol-myristate-acetate induced chromosome breakage by antioxidants and inhibitors of arachidonic acid metabolism, Mutat. Res. 110:327 (1983).PubMedCrossRefGoogle Scholar
  11. 11.
    L. Gianni, B. J. Corden and C. E. Meyers, The biochemical basis of anthracycline toxicity and antitumor action, in Reviews in Biochemical Toxicology, Vol. 5, E. Hodson, J. R. Bend and R. M. Philpot (eds.), Elsevier, Amsterdam (1983).Google Scholar
  12. 12.
    J. W. Lown, H-H. Chen, J. A. Plambeck and E. M. Acton, Further studies on the generation of reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effects, Biochem. Pharmacol. 31:575 (1982).PubMedCrossRefGoogle Scholar
  13. 13.
    B. Chance, H. Sies and A. Boveris, Hydroperoxide metabolism in mammalian organs, Physiol. Rev. 59:527 (1979).PubMedGoogle Scholar
  14. 14.
    J. F. Mead, Free radical mechanism of lipid damage and consequences for cellular membranes, in Free Radicals in Biology, W. A. Pryor (ed.), Academic Press, New York (1976).Google Scholar
  15. 15.
    K. Reszka, P. Kolodziejczyk and J. W. Lown, Horseradish peroxidase-catalyzed oxidation of mitoxantrone, Spectrophotometric and electron paramagnetic resonance studies, J. Free Rad. Biol. Med. 2:25 (1986).Google Scholar
  16. 16.
    P. Kolodziejczyk, K. Reszka and J. W. Lown, Enzymatic oxidative activation and transformation of the antitumor agent mitoxantrone, Free Radical Biol. Med. 5:13 (1988).CrossRefGoogle Scholar
  17. 17.
    P. Kolodziejczyk, K. Reszka and J. W. Lown, Oxidative activation of 5-iminodaunorubicin; action of horseradish peroxidase, Spectroscopic and electron paramagnetic resonance studies, Biochem. Pharmacol. in press (1989).Google Scholar
  18. 18.
    E. D. Kharash and R. F. Novak, Structural and mechanistic differences in quinone inhibition of microsomal drug metabolism; inhibition of NADPH-cytochrome P-450 reductase activity in cytochrome P-450, Developments in Biochemistry 23:623 (1983).Google Scholar
  19. 19.
    J. Basra, C. R. Wolf, J. R. Brown and L. H. Patterson, Evidence for human liver mediated Free radical formation by doxorubicin and mitoxantrone, Anticancer Drug Design 1:45(1985).Google Scholar
  20. 20.
    P. Kolodziejczyk, K. Reszka and J. W. Lown, Alternative to the bioreductive activation of anthracyclines: Enzymatic oxidative metabolism of anthracenediones, 5-iminodaunorubicin and anthrapyrazoles, in Oxy-radicals in Molecular Biology and Pathology, Vol. 82, P. A. Cerutti, I. Fridovich, J. M. McCord (eds.), A. R. Liss, New York (1988).Google Scholar
  21. 21.
    B. Meunier, Horseradish peroxidase: A useful tool for modeling the extrahepatic biooxidation of exogens, Biochimie 69:3 (1987).PubMedCrossRefGoogle Scholar
  22. 22.
    P. Frank and R. F. Novak, Effects of anthrapyrazole antineoplastic agents on lipid peroxidation, Biochem. Biophys. Res. Commun. 140:797 (1986).PubMedCrossRefGoogle Scholar
  23. 23.
    B. Testa and P. Jenner, Inhibitors of cytochrome P-450s and their mechanism of action, Drug Metabolism Reviews 12:1 (1981).PubMedCrossRefGoogle Scholar
  24. 24.
    R. A. Neal, T. Sawahata, J. Halpert and T. Kamataki, Chemically reactive metabolites as suicide enzyme inhibitors, Drug Metabolism Reviews 14:49 (1983).PubMedCrossRefGoogle Scholar
  25. 25.
    R. K. Boutwell, Retinoids and prostaglandin synthesis inhibitors as protective agents against chemical carcinogenesis and tumor promotion, in Radioprotectors and Anticarcinogens, O. F. Nygaard, M. G. Simic (eds.), Academic Press, New York (1983).Google Scholar
  26. 26.
    J. M. McCord, Superoxide radical: A likely link between reperfusion injury and inflammation, Adv. Free Rad. Biol. Med. 2:325 (1986).CrossRefGoogle Scholar
  27. 28.
    M. J. Waring, Overview of the interaction between chemotherapeutic agents and DNA, Drugs Exptl. Clin. Res. 12:441 (1986).Google Scholar
  28. 29.
    W. E. M. Lands, Interactions of lipid hydroperoxides with eicosanoid biosynthesis, J. Free Rad. Biol. Med. 1:97 (1985).CrossRefGoogle Scholar
  29. 30.
    K. V. Honn, R. S. Bockman and L. J. Marnett, Prostaglandins and cancer: A review of tumor initiation through tumor metastasis, Prostaglandins 21:833 (1983).CrossRefGoogle Scholar
  30. 31.
    A. Aitokallio-Tallbert, J. Karkkainen, P. Pantzar, T. Wahlstrom, and O. Ylikorkala, Prostaglandin and thromboxane in breast cancer: Relationship between steroid receptor status and medroxyprogesterone-acetate, Br. J. Cancer 5:671 (1985).CrossRefGoogle Scholar
  31. 32.
    A. M. Aitokallio-Tallberg, L. V. Viinikka and R. O. Ylikorkala, Increased synthesis of prostacyclin and thromboxane in human ovarian malignancy, Cancer Res. 48:23968 (1988).Google Scholar
  32. 33.
    R. W. Egan, P. H. Gale, G. C. Beveridge, L. J. Marnett and F. A. Keuhl, Direct and indirect involvement of radical scavengers during prostaglandin biosynthesis, Adv. Prostaglandin Thromboxane Res. 6:153 (1980).PubMedGoogle Scholar
  33. 34.
    J. Capdevila, R. W. Estabrook and R. A. Prough, Differences in the mechanism of NADPH and cumene hydroperoxide-supported reactions of cytochrome P-450, Arch. Biochem. Biophys. 200:186 (1980).PubMedCrossRefGoogle Scholar
  34. 35.
    E. L. Wheeler, Cytochrome P-450 mediated interaction between hydroperoxide and molecular oxygen, Biochem. Biophys. Res. Commun. 110:646 (1983).PubMedCrossRefGoogle Scholar
  35. 36.
    J. C. Sircar, C. F. Schwender and E. A. Johnson, Soybean lipoxygenase inhibition by nonsteroidal antiinflammatory drugs, Prostaglandins 25:393 (1983).PubMedCrossRefGoogle Scholar
  36. 37.
    R. H. Tullman and R. P. Hanzlik, Inactivation of cytochrome P-450 and monoamine oxidase by cyclopropylamines, Drug Metabolism Review 15:11632 (1984).CrossRefGoogle Scholar
  37. 38.
    C. Baarnhielm and G. Hansson, Oxidation of 1,4-dihydropyridines by prostaglandin synthase and the peroxic function of cytochrome P-450, Demonstration of a free radical intermediate, Biochem. Pharmacol. 35:14195 (1986).Google Scholar
  38. 39.
    R. F. Novak, E. D. Kharasch, P. Frank and M. Runge-Morris, Anthracyclines, anthracenediones and anthrapyrazoles: Comparison of redox cycling activity and effects on lipid peroxidation and prostaglandin production, in Anthracycline and Anthracenedione Anticancer Agents, J. W. Lown (ed.), Elsevier, Amsterdam (1989).Google Scholar
  39. 40.
    P. Lesca, P. Lecointe, C. Paoletti and D. Mansuy, Ellipticines as potent inhibitors of drug metabolism: Protective effect against chemical mutagenesis and carcinogenesis, Biochemie 60:1011 (1978).CrossRefGoogle Scholar
  40. 41.
    L. Levine, Arachidonic acid transformation and tumor production, Adv. Cancer Res. 35:49(1981).PubMedCrossRefGoogle Scholar
  41. 42.
    E. Carafoli, Intracellular calcium homeostasis, Annu. Rev. Biochem. 56:395 (1987).PubMedCrossRefGoogle Scholar
  42. 43.
    C. Richter and B. Frei, Ca2+ release from mitochondria induced by prooxidants, Free Rad. Biol. Med. 4:365 (1988).PubMedCrossRefGoogle Scholar
  43. 44.
    C. Richter, B. Frei and P. A. Cerutti, Mobilization of mitochondrial Ca2+ by hydroperoxyeicosatetraenoic acid, Biochem. Biophys. Res. Commun. 143:609 (1987).PubMedCrossRefGoogle Scholar
  44. 45.
    N. Yamanaka, T. Kato, K. Nishida, T. Fujikawa, M. Fukushima and K. Ota, Elevation of serum lipid peroxide level associated with doxorubicin toxicity and its amelioration by d,I-alpha tocopherol acetate or coenzyme Q10 in mouse, Cancer Chemother. Pharmacol. 3:223 (1979).Google Scholar
  45. 46.
    H. M. Olson and C. C. Capen, Chronic cardiotoxicity of doxorubicin (adriamycin) in the rat: Morphologic and biochemical investigations, Toxicol. Appl. Pharmacol. 44:605 (1978).PubMedCrossRefGoogle Scholar
  46. 47.
    M. Moore, H. Thor, G. Moore, S. Nelson, P. Moldeus and S. Orrenius, The toxicity of acetaminophen and N-acetyl-p-benzoquinone imine in isolated hepatocytes is associated with thiol depletion and increased cytosolic Ca2+, J. Biol. Chem. 24:13035 (1985).Google Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Pawel Kolodziejczyk
    • 1
  • J. William Lown
    • 1
  1. 1.Department of ChemistryUniversity of AlbertaEdmontonCanada

Personalised recommendations